Stallergenes pursues FDA approval for sublingual allergy tablet

Stallergenes filed with the FDA to sell a first-of-its-kind sublingual allergy medication in the U.S., furthering the company's ongoing international expansion.

The French company is seeking a Biologics License Agreement with U.S. authorities for its oral allergen immunotherapy, Oralair.

During allergen immunotherapy, a patient is dosed with a small amount of the allergic substance. By introducing allergens such as pollen or dust mites, the process is meant to rehabilitate the immune system and encourage long-term tolerance. The current standard of care for allergic rhinitis, a severe respiratory disease that affects 60 million people in the U.S., is for a medical professional to perform a series of injections.

But Stallergenes' tablet is taken under the tongue and contains 5 of the pollen extracts at the root of many allergies: Perennial Ryegrass, Kentucky Bluegrass, Timothy Grass, Orchard Grass and Sweet Vernal Grass. By forgoing the needle delivery, a patient can take the tablet at home.

Oralair is available in Europe, Australia, New Zealand, Russia and, as of a few months ago, Canada. Stallergenes has been extending its reach to several of these markets in the last few years, making international expansion a priority.

This isn't the first time Stallergenes has looked to gain traction in the U.S. Back in 2010, the company looked for American partners to ultimately market Oralair. Merck ($MRK) also looks to take a chunk of the market with its yet-unapproved allergy tablet Grazax.

- here's the release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…